Can Moderna Meet Its COVID Vaccine Expectations?
Non-Profit Competition Will Hit Revenues
Analysts have cut forecasts for Moderna’s COVID-19 vaccine – but there is still much to play for as key readouts approach.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical sector.
Company receives a base payment of $1.225bn for the manufacturing and delivery of the first 100 million disease, plus a bonus if mRNA-1273 reaches the market quickly.
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.